285 related articles for article (PubMed ID: 33639165)
1. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus.
Vitner EB; Achdout H; Avraham R; Politi B; Cherry L; Tamir H; Yahalom-Ronen Y; Paran N; Melamed S; Erez N; Israely T
J Biol Chem; 2021; 296():100470. PubMed ID: 33639165
[TBL] [Abstract][Full Text] [Related]
2. Elevation in sphingolipid upon SARS-CoV-2 infection: possible implications for COVID-19 pathology.
Vitner EB; Avraham R; Politi B; Melamed S; Israely T
Life Sci Alliance; 2022 Jan; 5(1):. PubMed ID: 34764206
[TBL] [Abstract][Full Text] [Related]
3. Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation.
Lim YS; Nguyen LP; Lee GH; Lee SG; Lyoo KS; Kim B; Hwang SB
Mol Cells; 2021 Sep; 44(9):688-695. PubMed ID: 34518443
[TBL] [Abstract][Full Text] [Related]
4. p-cymene impairs SARS-CoV-2 and Influenza A (H1N1) viral replication: In silico predicted interaction with SARS-CoV-2 nucleocapsid protein and H1N1 nucleoprotein.
Panagiotopoulos A; Tseliou M; Karakasiliotis I; Kotzampasi DM; Daskalakis V; Kesesidis N; Notas G; Lionis C; Kampa M; Pirintsos S; Sourvinos G; Castanas E
Pharmacol Res Perspect; 2021 Aug; 9(4):e00798. PubMed ID: 34128351
[TBL] [Abstract][Full Text] [Related]
5. Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity.
Rand U; Kupke SY; Shkarlet H; Hein MD; Hirsch T; Marichal-Gallardo P; Cicin-Sain L; Reichl U; Bruder D
Cells; 2021 Jul; 10(7):. PubMed ID: 34359926
[TBL] [Abstract][Full Text] [Related]
6. Viruses harness YxxØ motif to interact with host AP2M1 for replication: A vulnerable broad-spectrum antiviral target.
Yuan S; Chu H; Huang J; Zhao X; Ye ZW; Lai PM; Wen L; Cai JP; Mo Y; Cao J; Liang R; Poon VK; Sze KH; Zhou J; To KK; Chen Z; Chen H; Jin DY; Chan JF; Yuen KY
Sci Adv; 2020 Aug; 6(35):eaba7910. PubMed ID: 32923629
[TBL] [Abstract][Full Text] [Related]
7. Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice.
Muturi E; Hong W; Li J; Yang W; He J; Wei H; Yang H
Int J Antimicrob Agents; 2022 Jan; 59(1):106499. PubMed ID: 34929295
[TBL] [Abstract][Full Text] [Related]
8. Construction of a Noninfectious SARS-CoV-2 Replicon for Antiviral-Drug Testing and Gene Function Studies.
Nguyen HT; Falzarano D; Gerdts V; Liu Q
J Virol; 2021 Aug; 95(18):e0068721. PubMed ID: 34191580
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
[TBL] [Abstract][Full Text] [Related]
10. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
11.
Liu H; Ye F; Sun Q; Liang H; Li C; Li S; Lu R; Huang B; Tan W; Lai L
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):497-503. PubMed ID: 33491508
[TBL] [Abstract][Full Text] [Related]
12. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
[TBL] [Abstract][Full Text] [Related]
13. Cirsimaritin inhibits influenza A virus replication by downregulating the NF-κB signal transduction pathway.
Yan H; Wang H; Ma L; Ma X; Yin J; Wu S; Huang H; Li Y
Virol J; 2018 May; 15(1):88. PubMed ID: 29783993
[TBL] [Abstract][Full Text] [Related]
14. Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses.
Lu S; Pan X; Chen D; Xie X; Wu Y; Shang W; Jiang X; Sun Y; Fan S; He J
Bioorg Chem; 2021 Feb; 107():104619. PubMed ID: 33450541
[TBL] [Abstract][Full Text] [Related]
15. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air-Liquid Interface Cultured Human Primary Bronchial Epithelial Cells.
Ter Ellen BM; Dinesh Kumar N; Bouma EM; Troost B; van de Pol DPI; van der Ende-Metselaar HH; Apperloo L; van Gosliga D; van den Berge M; Nawijn MC; van der Voort PHJ; Moser J; Rodenhuis-Zybert IA; Smit JM
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372541
[TBL] [Abstract][Full Text] [Related]
17. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
18. Aprotinin Inhibits SARS-CoV-2 Replication.
Bojkova D; Bechtel M; McLaughlin KM; McGreig JE; Klann K; Bellinghausen C; Rohde G; Jonigk D; Braubach P; Ciesek S; Münch C; Wass MN; Michaelis M; Cinatl J
Cells; 2020 Oct; 9(11):. PubMed ID: 33143316
[TBL] [Abstract][Full Text] [Related]
19. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
20. Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.
Schuhenn J; Meister TL; Todt D; Bracht T; Schork K; Billaud JN; Elsner C; Heinen N; Karakoese Z; Haid S; Kumar S; Brunotte L; Eisenacher M; Di Y; Lew J; Falzarano D; Chen J; Yuan Z; Pietschmann T; Wiegmann B; Uebner H; Taube C; Le-Trilling VTK; Trilling M; Krawczyk A; Ludwig S; Sitek B; Steinmann E; Dittmer U; Lavender KJ; Sutter K; Pfaender S
Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35131898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
